Immune-mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure.
ADAMTS13
blood pressure
complement
hemolytic uremic syndrome
hypertension
prognosis
thrombotic microangiopathies
thrombotic thrombocytopenic purpura
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
10
11
2021
revised:
04
03
2022
accepted:
13
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
The prevalence, prognostic role, and diagnostic value of blood pressure in immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs) remain unclear. Using a national cohort of iTTP ( Patients with iTTP had lower blood pressure than patients with other TMAs, systolic (130 [interquartile range (IQR) 118-143] vs 161 [IQR 142-180] mmHg) and diastolic (76 [IQR 69-83] vs 92 [IQR 79-105] mmHg, both Elevated blood pressure at admission affects the prognosis of iTTP patients and may help discriminate them from other TMA patients. Particular attention should be paid to blood pressure and its management in these patients.
Sections du résumé
Background
UNASSIGNED
The prevalence, prognostic role, and diagnostic value of blood pressure in immune-mediated thrombotic thrombocytopenic purpura (iTTP) and other thrombotic microangiopathies (TMAs) remain unclear.
Methods
UNASSIGNED
Using a national cohort of iTTP (
Results
UNASSIGNED
Patients with iTTP had lower blood pressure than patients with other TMAs, systolic (130 [interquartile range (IQR) 118-143] vs 161 [IQR 142-180] mmHg) and diastolic (76 [IQR 69-83] vs 92 [IQR 79-105] mmHg, both
Conclusions
UNASSIGNED
Elevated blood pressure at admission affects the prognosis of iTTP patients and may help discriminate them from other TMA patients. Particular attention should be paid to blood pressure and its management in these patients.
Identifiants
pubmed: 35599703
doi: 10.1002/rth2.12702
pii: S2475-0379(22)01208-0
pmc: PMC9115975
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12702Informations de copyright
© 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Hypertension. 2008 Apr;51(4):862-6
pubmed: 18332284
N Engl J Med. 2019 Jan 24;380(4):335-346
pubmed: 30625070
Clin J Am Soc Nephrol. 2019 Apr 5;14(4):557-566
pubmed: 30862697
Hypertension. 2020 Feb;75(2):422-430
pubmed: 31865800
Res Pract Thromb Haemost. 2022 May 18;6(4):e12702
pubmed: 35599703
Haematologica. 2019 Dec;104(12):2501-2511
pubmed: 30890598
PLoS One. 2017 May 18;12(5):e0177894
pubmed: 28542627
Transfusion. 2021 Jan;61(1):266-273
pubmed: 33179792
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Br J Haematol. 2008 Sep;142(5):819-26
pubmed: 18637802
N Engl J Med. 2013 Jun 6;368(23):2169-81
pubmed: 23738544
Lancet. 2017 Aug 12;390(10095):681-696
pubmed: 28242109
Kidney Int Rep. 2017 Jun 21;2(6):1088-1095
pubmed: 29270517
Blood. 2013 Sep 19;122(12):2023-9; quiz 2142
pubmed: 23838348
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
J Am Soc Hypertens. 2016 Apr;10(4):352-9
pubmed: 26778772
PLoS One. 2010 Apr 23;5(4):e10208
pubmed: 20436664
Kidney Int. 2019 Oct;96(4):995-1004
pubmed: 31420192
Lancet Haematol. 2017 Apr;4(4):e157-e164
pubmed: 28259520
Thromb Haemost. 2019 May;119(5):695-704
pubmed: 30861548
Res Pract Thromb Haemost. 2018 Nov 16;3(1):26-37
pubmed: 30656273
Lancet Haematol. 2016 May;3(5):e237-45
pubmed: 27132698
Am J Kidney Dis. 2010 Dec;56(6):1168-74
pubmed: 20843591
J Thromb Haemost. 2017 Feb;15(2):312-322
pubmed: 27868334
Blood. 2019 Dec 12;134(24):2209-2217
pubmed: 31530564